Korro Bio (KRRO) to Release Quarterly Earnings on Wednesday

Key Points

• Q1 2026 results due May 6 (pre-market); analysts expect a loss of ($1.7267) per share and revenue of $0.761 million, with the company’s conference call set for May 13 at 4:00 PM ET.
• In the prior quarter Korro Bio reported a large miss—EPS ($5.32) vs. consensus ($1.93)—and showed severely negative profitability (ROE -115.95%, net margin -1,834.48%); analysts project roughly -$5 EPS for the current fiscal year and -$6 for the next.
• Despite weak fundamentals, insiders bought heavily (1.657 million shares worth about $18.4M over three months) and several analysts have upgraded the name, leaving a consensus rating of “Moderate Buy” with a $37.29 price target while shares trade near $12.80.

Korro Bio (NASDAQ:KRRO - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($1.7267) per share and revenue of $0.7610 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing the consensus estimate of ($1.93) by ($3.39). Korro Bio had a negative return on equity of 115.95% and a negative net margin of 1,834.48%.The business had revenue of $1.29 million during the quarter, compared to analysts' expectations of $0.43 million. On average, analysts expect Korro Bio to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Korro Bio Stock Performance

Shares of NASDAQ KRRO opened at $12.80 on Wednesday. The business's 50 day moving average price is $12.27 and its 200-day moving average price is $14.90. Korro Bio has a fifty-two week low of $5.20 and a fifty-two week high of $55.89. The company has a market cap of $184.58 million, a price-to-earnings ratio of -1.03 and a beta of 3.20.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on KRRO shares. Raymond James Financial upgraded Korro Bio from a "market perform" rating to an "outperform" rating and set a $23.00 price target on the stock in a report on Friday, March 13th. Clear Str upgraded Korro Bio from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 18th. William Blair upgraded Korro Bio from a "market perform" rating to an "outperform" rating in a report on Tuesday, February 17th. Weiss Ratings restated a "sell (d-)" rating on shares of Korro Bio in a report on Wednesday, April 8th. Finally, Cantor Fitzgerald raised their price objective on Korro Bio from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $37.29.

Insider Activity at Korro Bio

In other news, major shareholder Mohamad Makhzoumi acquired 207,100 shares of Korro Bio stock in a transaction on Tuesday, March 10th. The shares were bought at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the acquisition, the insider directly owned 1,297,893 shares of the company's stock, valued at $14,419,591.23. This trade represents a 18.99% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Edward T. Mathers acquired 207,100 shares of Korro Bio stock in a transaction on Tuesday, March 10th. The shares were purchased at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares in the company, valued at $14,419,591.23. This trade represents a 18.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 1,657,320 shares of company stock worth $18,412,560 over the last three months. Corporate insiders own 4.60% of the company's stock.

Institutional Trading of Korro Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC bought a new stake in Korro Bio during the 4th quarter valued at $4,806,000. TCG Crossover Management LLC bought a new stake in Korro Bio during the 3rd quarter valued at $19,937,000. Vanguard Group Inc. boosted its position in Korro Bio by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company's stock valued at $18,948,000 after acquiring an additional 8,921 shares in the last quarter. Polar Capital Holdings Plc boosted its position in Korro Bio by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company's stock valued at $12,676,000 after acquiring an additional 14,694 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company's stock valued at $12,467,000 after acquiring an additional 4,650 shares in the last quarter. Institutional investors own 13.18% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.